← FDA DRUG APPROVALS

FDA ANDA · ANDA040620

METHYLPREDNISOLONE ACETATE

Sponsor: TEVA PHARMS USA

APPLICATION
ANDA040620
TYPE
ANDA
ORIGINAL APPROVAL
2006-10-27
LATEST ACTION
2022-08-24
ROUTE
INJECTION
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Discontinued

Products

METHYLPREDNISOLONE ACETATEDiscontinued
METHYLPREDNISOLONE ACETATE 80MG/ML · INJECTABLE · INJECTION
METHYLPREDNISOLONE ACETATEDiscontinued
METHYLPREDNISOLONE ACETATE 40MG/ML · INJECTABLE · INJECTION

Approval history

2022-08-24Labeling · Supplement 31 · standardAP
2020-08-09Labeling · Supplement 26 · standardAP
2020-08-09Labeling · Supplement 24 · standardAP
2020-08-09Labeling · Supplement 30 · standardAP
2020-08-09Labeling · Supplement 22 · standardAP
2010-11-30Labeling · Supplement 3AP
2006-10-27OriginalReviewAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →